Across TCGA pan-cancer cohorts, SPATA21 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPATA21 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SPATA21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA21 expression acts as an unfavorable survival marker.

COAD, BLCA, and UCEC are the cancer types where SPATA21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.159	0.801	.001	36	view →
BLCA	OS	Median	All	0.210	0.610	.015	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SPATA21 tumor-vs-normal RNA expression · all SPATA21 data types